Shares of Cancer Therapy Company Athenex Gain Steam in IPO Debut
Athenex shares surged some 15% Wednesday following its debut as a public company on the Nasdaq.
Athenex (ANTX) shares surged some 15% Wednesday following its debut as a public company on the Nasdaq.
The biopharmaceuticals company posted a net loss in 2016 and expects to see losses for the "foreseeable future" according to its S-1 filing.
TheStreet's Scott Gamm speaks with Johnson Lau, Athenex's CEO.
